Vanda rejects Future Pak and Cycle Pharma`s takeover offers
England-based rare disease drug maker Cycle Pharma revealed an $8-per-share offer for Vanda, representing a total buyout offer of $466 million.
Cycle Pharmaceuticals Announces All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share
WASHINGTON, May 30, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Jefferies 2024 Global Healthcare Conference in New York City on Thursday, June 6, 2024. A corporate presentation is scheduled for 2:00 p.m. Eastern Time.
WASHINGTON, May 29, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at SLEEP 2024, to be held in Houston, TX from June 1 through June 5, 2024.
WASHINGTON, May 30, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that ownership of the U.S. New Drug Application and Investigational New Drug Applications for PONVORY® (ponesimod) has been transferred to Vanda from a Johnson & Johnson Company, which now fully allows Vanda to commercialize PONVORY® in the U.S.